文献速递临床试验与 GCP真实世界研究与卫生经济

针对房颤合并肥胖患者在心臟康复中实施「小改变」行为减重治疗的随机对照试验:BE-WEL in CR-AF 研究方案

A randomized controlled trial of a "Small Changes" behavioral weight loss treatment delivered in cardiac rehabilitation for patients with atrial fibrillation and obesity: study protocol for the BE-WEL in CR-AF study.
PubMed 文献 · Trials · 2024-10-11

该随机对照试验方案旨在评估在心臟康复(CR)基础上加用「小改变」行为减重治疗(BWLT)能否使房颤合并肥胖患者实现临床相关(≥10%)的体重下降,并改善房颤症状、危险因素及健康相关生活质量。研究计划纳入120例成人患者,随机分为CR+BWLT组与单纯CR组,主要终点为52周时体重下降≥10%的受试者比例。

要点

  • 国际房颤指南推荐房颤合并肥胖(BMI≥30 kg/m2)患者减重以减轻症状负担、改善预后,但少有CR项目包含针对性减重治疗。
  • 该方案将评估CR+BWLT对比单纯CR在52周时实现≥10%体重下降的比例,并观察房颤症状、危险因素及生活质量。
  • 干预组接受12周每周一次团体虚拟BWLT课程,随后12周随访支持;单纯CR组接受12周监督运动及危险因素自我管理。

核心结论

  • 该临床试验将是首个证明在CR基础上加用BWLT可促进房颤合并肥胖患者实现有临床意义体重下降的研究。
  • 研究结果将为设计并实施以长期(如5年)临床终点(如房颤严重程度、死亡率)为目标的大型疗效试验提供依据。

研究设计与样本

  • 随机对照试验方案,招募18岁及以上房颤合并肥胖成人,随机分为CR+BWLT组(干预)或单纯CR组(对照)。
  • 对照组接受为期12周的监督运动及危险因素自我管理组成的CR;干预组接受CR加BWLT,包括12周每周一次团体虚拟课程,随后12周随访支持。
  • 计划纳入120例患者(每组60例),假设对照组和干预组成功率分别为5%和30%、失访率30%,采用双侧独立比例检验(α=5%)提供80%把握度检出差异。

主要发现

  • 主要终点为从基线至52周的体重下降百分比,采用意向性治疗分析比较各组实现≥10%体重下降的比例。
  • 将在随机化前、12周、24周和52周评估体重和房颤危险因素。
  • 房颤负荷将通过每两日记录一次30秒心电图及房颤症状进行评估。

关键数值与推荐

  • 国际房颤实践指南指出,房颤合并肥胖(BMI≥30 kg/m2)患者应减重以减轻症状负担并改善预后。
  • 主要终点为52周时实现≥10%体重下降的受试者比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF) represents a global epidemic. Although international AF practice guidelines indicate weight loss for patients with AF and comorbid obesity (BMI ≥ 30 kg/m2) to alleviate symptom burden and improve prognosis, few cardiac rehabilitation (CR) programs include targeted weight loss treatment. AIMS: This RCT protocol will evaluate the efficacy of a "Small Changes" behavioral weight loss treatment (BWLT) to produce clinically relevant (≥ 10%) weight loss among patients with AF and obesity undergoing CR, relative to CR alone. Secondary aims are to establish efficacy of CR + BWLT for improving AF symptoms, AF risk factors, and health-related quality of life. METHODS: Adults (18 +) with AF and obesity will be recruited and randomized to receive CR + BWLT (intervention) or CR-only (control). Controls will receive CR consisting of supervised exercise and risk factor self-management for 12 weeks. The intervention group will receive CR plus BWLT (12 weekly, group-based virtual sessions, followed by 12 weeks of follow-up support). Weight and AF-risk factors will be assessed at pre-randomization, 12 weeks, 24 weeks, and 52 weeks. AF burden will be assessed using 30-s ECGs recorded bidaily and with AF symptoms. The primary endpoint of weight loss will be calculated from baseline to 52 weeks as a percentage of starting weight. Intention-to-treat analyses will compare the proportion in each group achieving ≥ 10% weight loss. Assuming success rates of 5% and 30% among controls and intervention groups, respectively, and a 30% loss to follow-up, 120 patients (60 per group) will provide 80% power to detect a difference using a two-sided independent test of proportions (alpha = 5%). IMPACT: This clinical trial will be the first to demonstrate that adding BWLT to CR promotes clinically meaningful weight loss among patients with AF and comorbid obesity. Findings will inform design and execution of a large efficacy trial of long-term (e.g., 5-year) clinical endpoints (e.g., AF severity, mortality). Implementing weight control interventions designed to target the AF substrate in CR could dramatically reduce morbidity and enhance quality of life among patients living with AF in Canada. TRIAL REGISTRATION: ClinicalTrials.gov registration number: NCT05600829. Registered October 31, 2022.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Williamson TM, Rouleau CR, Wilton SB, et al. A randomized controlled trial of a "Small Changes" behavioral weight loss treatment delivered in cardiac rehabilitation for patients with atrial fibrillation and obesity: study protocol for the BE-WEL in CR-AF study. Trials. 2024. PMID: 39394158. doi:10.1186/s13063-024-08527-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。